|
1
|
Wani HA, Beigh MA, Amin S, et al:
Methylation profile of promoter region of p16 gene in colorectal
cancer patients of Kashmir valley. J Biol Regul Homeost Agents.
27:297–307. 2013.PubMed/NCBI
|
|
2
|
Kheirelseid EA, Miller N, Chang KH, et al:
Clinical applications of gene expression in colorectal cancer. J
Gastrointest Oncol. 4:144–57. 2013.PubMed/NCBI
|
|
3
|
Liao YX, Zhou CH, Zeng H, et al: The role
of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of
bone sarcomas (Review). Int J Mol Med. 32:1239–1246.
2013.PubMed/NCBI
|
|
4
|
Ratajczak MZ, Kim C, Janowska-Wieczorek A,
et al: The expanding family of bone marrow homing factors for
hematopoietic stem cells: stromal derived factor 1 is not the only
player in the game. Sci World J. 2012:7585122012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang L, Chen W, Gao L, et al: High
expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in
renal cell carcinoma. World J Surg Oncol. 10:2122012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Monnier J, Boissan M, L’Helgoualc’h A, et
al: CXCR7 is up-regulated in human and murine hepatocellular
carcinoma and is specifically expressed by endothelial cells. Eur J
Cancer. 48:138–148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hattermann K, Held-Feindt J, Lucius R, et
al: The chemokine receptor CXCR7 is highly expressed in human
glioma cells and mediates antiapoptotic effects. Cancer Res.
70:3299–3308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gahan JC, Gosalbez M, Yates T, et al:
Chemokine and chemokine receptor expression in kidney tumors:
molecular profiling of histological subtypes and association with
metastasis. J Urol. 187:827–833. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Z, Sun DX, Teng XY, et al: Expression
of stromal cell-derived factor 1 and CXCR7 in papillary thyroid
carcinoma. Endocr Pathol. 23:247–253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ehrlich A, Ray P, Luker KE, et al:
Allosteric peptide regulators of chemokine receptors CXCR4 and
CXCR7. Biochem Pharmacol. 86:1263–1271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hattermann K and Mentlein R: An infernal
trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in
tumor biology. Ann Anat. 195:103–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schrevel M, Karim R, ter Haar NT, et al:
CXCR7 expression is associated with disease-free and
disease-specific survival in cervical CXCR7 patients. Br J Cancer.
106:1520–1525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Odemis V, Lipfert J, Kraft R, et al: The
presumed atypical chemokine receptor CXCR7 signals through G (i/o)
proteins in primary rodent astrocytes and human glioma cells. Glia.
60:372–381. 2012. View Article : Google Scholar
|
|
14
|
Wijtmans M, Maussang D, Sirci F, et al:
Synthesis, modeling and functional activity of substituted
styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem.
51:184–192. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maussang D, Mujić-Delić A, Descamps FJ, et
al: Llama-derived single variable domains (nanobodies) directed
against chemokine receptor CXCR7 reduce head and neck cancer cell
growth in vivo. J Biol Chem. 288:29562–29572. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McGinn OJ, Marinov G, Sawan S, et al:
CXCL12 receptor preference, signal transduction, biological
response and the expression of 5T4 oncofoetal glycoprotein. J Cell
Sci. 125:5467–5478. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hao M, Zheng J, Hou K, et al: Role of
chemokine receptor CXCR7 in bladder cancer progression. Biochem
Pharmacol. 84:204–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang T, Xia QJ, Chen JB, et al: Expression
of the CXCL12/SDF-1 chemokine receptor CXCR7 in human brain
tumours. Asian Pac J Cancer Prev. 13:5281–5286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goguet-Surmenian E, Richard-Fiardo P,
Guillemot E, et al: CXCR7-mediated progression of osteosarcoma in
the lungs. Br J Cancer. 109:1579–1585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gebauer F, Tachezy M, Effenberger K, et
al: Prognostic impact of CXCR4 and CXCR7 expression in pancreatic
adenocarcinoma. J Surg Oncol. 104:140–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo JC, Li J, Yang YC, et al:
Oligonucleotide microarray identifies genes differentially
expressed during tumorigenesis of DMBA-induced pancreatic cancer in
rats. PLoS One. 8:e829102013. View Article : Google Scholar
|
|
22
|
Baumhoer D, Smida J, Zillmer S, et al:
Strong expression of CXCL12 is associated with a favorable outcome
in osteosarcoma. Mod Pathol. 25:522–528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zabel BA, Lewén S, Berahovich RD, et al:
The novel chemokine receptor CXCR7 regulates trans-endothelial
migration of cancer cells. Mol Cancer. 10:732011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng K, Li HY, Su XL, et al: Chemokine
receptor CXCR7 regulates the invasion, angiogenesis and tumor
growth of human hepatocellular carcinoma cells. J Exp Clin Cancer
Res. 29:312010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hattermann K, Mentlein R and Held-Feindt
J: CXCL12 mediates apoptosis resistance in rat C6 glioma cells.
Oncol Rep. 27:1348–1352. 2012.PubMed/NCBI
|
|
26
|
Guillemot E, Karimdjee-Soilihi B, Pradelli
E, et al: CXCR7 receptors facilitate the progression of colon
carcinoma within lung not within liver. Br J Cancer. 107:1944–1949.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Heinrich EL, Lee W, Lu J, et al: Chemokine
CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways
in pancreatic cancer cells. J Transl Med. 10:682012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ray P, Mihalko LA, Coggins NL, et al:
Carboxy-terminus of CXCR7 regulates receptor localization and
function. Int J Biochem Cell Biol. 44:669–678. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu L, Zhao X, Zhu X, et al: Decreased
expression of miR-430 promotes the development of bladder cancer
via the upregulation of CXCR7. Mol Med Rep. 8:140–146.
2013.PubMed/NCBI
|
|
30
|
Risio M: Cell proliferation in colorectal
tumor progression: an immunohistochemical approach to intermediate
biomarkers. J Cell Biochem (Suppl). 16G:79–87. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liabakk NB, Talbot I, Smith RA, et al:
Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9
(MMP-9) type IV collagenases in colorectal cancer. Cancer Res.
56:190–196. 1996.
|
|
32
|
Devarajan E, Sahin AA, Chen JS, et al:
Downregulation of caspase 3 in breast cancer: a possible mechanism
for chemoresistance. Oncogene. 21:8843–8851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong S, Kong J, Kong F, et al:
Insufficient radiofrequency ablation promotes
epithelial-mesenchymal transition of hepatocellular carcinoma cells
through Akt and ERK signaling pathways. J Transl Med. 11:2732013.
View Article : Google Scholar
|
